Provided by Tiger Trade Technology Pte. Ltd.

Atrium Therapeutics

13.64
-0.3400-2.43%
Post-market: 13.640.00000.00%19:30 EDT
Volume:108.64K
Turnover:1.48M
Market Cap:233.32M
PE:-3.54
High:13.95
Open:13.87
Low:13.51
Close:13.98
52wk High:16.77
52wk Low:11.13
Shares:17.11M
Float Shares:15.72M
Volume Ratio:0.69
T/O Rate:0.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8578
EPS(LYR):-3.1905
ROE:-43.98%
ROA:-399.25%
PB:1.09
PE(LYR):-4.28

Loading ...

Atrium Therapeutics - Eligible for up to $1.35 Bln R&D Milestones, $825 Mln Commercial Milestones, Tiered Royalties

THOMSON REUTERS
·
Aug 13

Atrium Therapeutics - Bristol Myers Squibb to Fund All Future Development and Commercialization Activities

THOMSON REUTERS
·
Aug 13

CSPC Pharma (01093) Receives FDA Clearance for US Clinical Trial of Monkeypox mRNA Vaccine

Stock News
·
Aug 10

HC Wainwright Initiates Atrium Therapeutics at Buy, With $25 Price Target

MT Newswires Live
·
Aug 06

U.S. Research Roundup-Caterpillar, Eli Lilly, McKesson

Reuters
·
Aug 06

Circio’s circVec gene therapy platform secures oral slot at top European ESGCT conference

TIPRANKS
·
Aug 06

Wave Life Sciences to Present at Upcoming Investor Conferences

GlobeNewswire
·
Aug 04

Circio Strengthens Board With RNA Therapy Veterans Ahead of Clinical Push

TIPRANKS
·
Aug 04

Noxopharm Data Validate TLR8-Targeted Oligonucleotide Cancer Strategy

TIPRANKS
·
Aug 04

Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances

TIPRANKS
·
Jul 31

Wave Life Sciences’ Earnings Call Highlights RNA Momentum

TIPRANKS
·
Jul 31

Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
Jul 30

Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026

GlobeNewswire
·
Jul 23

Atrium Therapeutics Grants New Hire Stock Options for 7,000 Shares at USD 11.76 Exercise Price

Reuters
·
Jul 21

Atrium Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 21

Thalia Therapeutics Targets Clinical-Stage Growth With Sanmirna Deal and RNA Pipeline Push

TIPRANKS
·
Jul 17

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

GlobeNewswire
·
Jul 16

Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA)

TIPRANKS
·
Jul 16

Atrium Therapeutics announces FDA clearance of ATR 1072 IND application

TIPRANKS
·
Jul 14

Atrium Therapeutics Publishes Investor Presentation on Precision RNA Medicines for Cardiac Diseases

Reuters
·
Jul 14